Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
766
archived clinical trials in
Cosmetic

Efficacy of Topical Cyclosporin for Ocular Rosacea
Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea
Status: Archived
2500 Rte 347 Bldg 24
mi
from
StonyBrook, NY
Efficacy of Topical Cyclosporin for Ocular Rosacea
Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea
Status: Archived
Updated: 1/1/1970
2500 Rte 347 Bldg 24
mi
from
StonyBrook, NY
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks
Status: Archived
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks
Status: Archived
Updated: 1/1/1970
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks
Status: Archived
Clinical Unit for Research Trials In Skin (CURTIS)
mi
from
Boston, MA
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks
Status: Archived
Updated: 1/1/1970
Clinical Unit for Research Trials In Skin (CURTIS)
mi
from
Boston, MA
Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation
Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation
Status: Archived
The Aesthetics Research Center
mi
from
Redwood City, CA
Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation
Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation
Status: Archived
Updated: 1/1/1970
The Aesthetics Research Center
mi
from
Redwood City, CA
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
The Laser Institute for Dermatology
mi
from
Santa Monica, CA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
The Laser Institute for Dermatology
mi
from
Santa Monica, CA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Cherry Creek Research, Inc
mi
from
Denver, CO
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Cherry Creek Research, Inc
mi
from
Denver, CO
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Longmont Clinic, PC
mi
from
Longmont, CO
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Longmont Clinic, PC
mi
from
Longmont, CO
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Deaconess Billings Clinic Research Center
mi
from
Billings, MT
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Deaconess Billings Clinic Research Center
mi
from
Billings, MT
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Compliant Clinical Research
mi
from
Olathe, KA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Compliant Clinical Research
mi
from
Olathe, KA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Hamzavi Dermatology
mi
from
Ft. Gratiot, MI
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Hamzavi Dermatology
mi
from
Ft. Gratiot, MI
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
DermDox
mi
from
Hazleton, PA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
DermDox
mi
from
Hazleton, PA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Minnesota Clinical Study Center
mi
from
Fridley, MN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Minnesota Clinical Study Center
mi
from
Fridley, MN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Skin Specialists, PC
mi
from
Omaha, NE
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Skin Specialists, PC
mi
from
Omaha, NE
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Derm Research, Inc
mi
from
Austin, TX
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Derm Research, Inc
mi
from
Austin, TX
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Metrolina Medical Research
mi
from
1, Charlotte, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Metrolina Medical Research
mi
from
1, Charlotte, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Wilmington Medical Research
mi
from
Wilmington, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Wilmington Medical Research
mi
from
Wilmington, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Piedmont Medical Research Associates
mi
from
Winston-Salem, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Piedmont Medical Research Associates
mi
from
Winston-Salem, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Palmetto Medical Research
mi
from
Mt Pleasant, SC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Palmetto Medical Research
mi
from
Mt Pleasant, SC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
East Tennessee Medical Research
mi
from
Johnson City, TN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
East Tennessee Medical Research
mi
from
Johnson City, TN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Tennessee Clinical Research Center
mi
from
Nashville, TN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Tennessee Clinical Research Center
mi
from
Nashville, TN
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Arlington Center for Dermatology
mi
from
Arlington, TX
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Arlington Center for Dermatology
mi
from
Arlington, TX
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Progressive Clinical Research
mi
from
Vista, CA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Progressive Clinical Research
mi
from
Vista, CA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Dermatology Consultants Inc
mi
from
High Point, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Dermatology Consultants Inc
mi
from
High Point, NC
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Dermatology Research Associates
mi
from
Los Angeles, CA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Dermatology Research Associates
mi
from
Los Angeles, CA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Madison Skin & Research, Inc.
mi
from
Madison, WI
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Archived
Updated: 1/1/1970
Madison Skin & Research, Inc.
mi
from
Madison, WI
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Vitiligo & Pigmentation Institute
mi
from
Los Angeles, CA
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Vitiligo & Pigmentation Institute
mi
from
Los Angeles, CA
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Therapeutics Clinical Research
mi
from
San Diego, CA
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Therapeutics Clinical Research
mi
from
San Diego, CA
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Hudson Dermatology
mi
from
Evansville, IN
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Hudson Dermatology
mi
from
Evansville, IN
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Michigan Center for Research Corp
mi
from
Clinton Township, MI
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Michigan Center for Research Corp
mi
from
Clinton Township, MI
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Academic Dermatology
mi
from
Albuquerque, NM
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Academic Dermatology
mi
from
Albuquerque, NM
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Skin Search of Rochester, Inc
mi
from
Rochester, NY
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Skin Search of Rochester, Inc
mi
from
Rochester, NY
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Oregon Medical Center, PC
mi
from
Portland, OR
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Oregon Medical Center, PC
mi
from
Portland, OR
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Derm Research, Inc
mi
from
Austin, TX
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Derm Research, Inc
mi
from
Austin, TX
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
J. Gary Booker, MD APMC
mi
from
Shreveport, LA
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
J. Gary Booker, MD APMC
mi
from
Shreveport, LA
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Suzanne Bruce & Associates, PA
mi
from
Houston, TX
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
Status: Archived
Updated: 1/1/1970
Suzanne Bruce & Associates, PA
mi
from
Houston, TX
Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds
Status: Archived
About Skin Dermatology
mi
from
Englewood, CO
Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds
Status: Archived
Updated: 1/1/1970
About Skin Dermatology
mi
from
Englewood, CO
Burn Scar Appearance After Treatment With Fractional Carbon Dioxide (CO2) Laser
Burn Scar Characteristics After Treatment With Fractional CO2 Laser: A Clinical and Histological Study
Status: Archived
Moy-Fincher Medical Group
mi
from
Los Angeles, CA
Burn Scar Appearance After Treatment With Fractional Carbon Dioxide (CO2) Laser
Burn Scar Characteristics After Treatment With Fractional CO2 Laser: A Clinical and Histological Study
Status: Archived
Updated: 1/1/1970
Moy-Fincher Medical Group
mi
from
Los Angeles, CA
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial
Status: Archived
Dermatology Consultants Inc
mi
from
High Point, NC
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial
Status: Archived
Updated: 1/1/1970
Dermatology Consultants Inc
mi
from
High Point, NC
Sleep and Behavior in Children With Cleft Palate
Sleep and Neurobehavioral Performance After Cleft Palate Repair
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Sleep and Behavior in Children With Cleft Palate
Sleep and Neurobehavioral Performance After Cleft Palate Repair
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Fractional Laser and Ultrasound for Striae Distensae
Comparison of Fractional Photothermolysis Alone Versus Fractional Photothermolysis Plus Intense Focused Ultrasound for Treatment of Striae Distensae: A Prospective Randomized Control Trial.
Status: Archived
Northwestern University
mi
from
Chicago, IL
Fractional Laser and Ultrasound for Striae Distensae
Comparison of Fractional Photothermolysis Alone Versus Fractional Photothermolysis Plus Intense Focused Ultrasound for Treatment of Striae Distensae: A Prospective Randomized Control Trial.
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Cryolipolysis and Subcision for Treatment of Cellulite
Comparison of the Efficacy Between Cryolipolysis and Subcision for Treatment of Cellulite: A Prospective Randomized Control Trial.
Status: Archived
Northwestern University
mi
from
Chicago, IL
Cryolipolysis and Subcision for Treatment of Cellulite
Comparison of the Efficacy Between Cryolipolysis and Subcision for Treatment of Cellulite: A Prospective Randomized Control Trial.
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Investigator-blinded, Randomized, Cross-over, Multiple Dose Phase I Study on Safety and Pharmacokinetics of Topically Applied Azelaic Acid Foam, 15% Compared to Azelaic Acid Gel, 15% in Subjects With Papulopustular Rosacea
Status: Archived
Novum Pharmaceutical Research Services of Nevada Inc.
mi
from
Las Vegas, NV
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Investigator-blinded, Randomized, Cross-over, Multiple Dose Phase I Study on Safety and Pharmacokinetics of Topically Applied Azelaic Acid Foam, 15% Compared to Azelaic Acid Gel, 15% in Subjects With Papulopustular Rosacea
Status: Archived
Updated: 1/1/1970
Novum Pharmaceutical Research Services of Nevada Inc.
mi
from
Las Vegas, NV
Middle Ear Pressure Disregulation in Cleft Palate Patients
Middle Ear Pressure Disregulation in Cleft Palate Patients: Form-Function Correlates
Status: Enrolling
Updated:  12/31/1969
ENT Research Center, Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Middle Ear Pressure Disregulation in Cleft Palate Patients
Middle Ear Pressure Disregulation in Cleft Palate Patients: Form-Function Correlates
Status: Enrolling
Updated: 12/31/1969
ENT Research Center, Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Potential Research Study Participant Registry
Potential Research Study Participant Registry
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Potential Research Study Participant Registry
Potential Research Study Participant Registry
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials